Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin’s lymphoma

Table 1 Hepatitis B virus reactivation in patients with lymphoma and treated with entecavir

Author	Patients (n)	Hematologic malignancy	Pre-treatment HBV markers	Prophylaxis with anti-viral drugs	Rituximab-based regimen	Time of HBV reactivation (during/after anti-tumor therapy)	Outcome (alive/died)	HBsAg clearance (yes/no)
Ferreira et al[22]	1	DLBCL	HBsAg-, anti-HBs+, anti-HBc-	No	Yes	0/1	0/1	NR
Niitsu et al[14]	6	DLBCL	HBsAg-	No	Yes	2/4	5/11	NR
Chung et al[15]	1	DLBCL	HBsAg-, anti-HBs+, anti-HBc+	No	Yes	1/0	0/1	0/1
Lee et al[16]	1	FL	HBsAg-, anti-HBs+	No	Yes	1/0	1/0	NR
Stange et al[17]	2	B cell lymphoma	unknown	No	Yes	2/0	1/1	NR
Brost et al[11]	4	AML and lymphoma	Unknown for all	1 Yes, 3 No	No	2/2	3/1	3/1
Sanchez et al[12]	1	CLL	HBsAg-	No	Yes	0/1	1/0	NR
Colson et al[13]	1	B cell lymphoma	HBsAg-, anti-HBs-, anti-HBc+	No	Yes	1/0	1/0	NR
Mimura et al[18]	3	B cell lymphoma	HBsAg+	Yes	Yes	0/3	3/0	NR
Matsue et al[19]	5	B cell lymphoma	HBsAg-	No	Yes	0/5	5/0	1/4
Wu et al[20]	1	DLBCL	HBsAg-, anti-HBc+	No	Yes	0/1	0/1	0/1
Fukushima et al[21]	2	NHL, DLBCL	HBsAg-	No	Yes	0/2	2/0	1/1

DLBCL: Diffuse large B cell lymphoma; FL: Follicular lymphoma; AML: Acute myeloid leukemia; CLL: Chronic lymphocytic leukemia; NHL: Non-Hodgkin’s lymphoma; NR: Not reported.

¹Patient died of lymphoma-related causes.